{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:28:48Z","timestamp":1788362928661,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["MJFF-019201"],"award-info":[{"award-number":["MJFF-019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["MJFF-019201"],"award-info":[{"award-number":["MJFF-019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["MJFF-019201"],"award-info":[{"award-number":["MJFF-019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["MJFF-019201"],"award-info":[{"award-number":["MJFF-019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["MJFF-019201"],"award-info":[{"award-number":["MJFF-019201"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disease for which no disease-modifying therapies exist. Preclinical and clinical evidence suggest that repeated exposure to intermittent hypoxia might have short- and long-term benefits in PD. In a previous exploratory phase I trial, we demonstrated that in-clinic intermittent hypoxia exposure is safe and feasible with short-term symptomatic effects on PD symptoms. The current study aims to explore the safety, tolerability, feasibility, and net symptomatic effects of a four-week intermittent hypoxia protocol, administered at home, in individuals with PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/Design<\/jats:title>\n                <jats:p>: This is a two-armed double-blinded randomized controlled trial involving 40 individuals with mild to moderate PD. Participants will receive 45\u00a0min of normobaric intermittent hypoxia (fraction of inspired oxygen 0.16 for 5\u00a0min interspersed with 5\u00a0min normoxia), 3 times a week for 4 weeks. Co-primary endpoints include nature and total number of adverse events, and a feasibility-tolerability questionnaire. Secondary endpoints include Movement Disorders Society-Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS) part II and III scores, gait tests and biomarkers indicative of hypoxic dose and neuroprotective pathway induction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial builds on the previous phase I trial and aims to investigate the safety, tolerability, feasibility, and net symptomatic effects of intermittent hypoxia in individuals with PD. Additionally, the study aims to explore induction of relevant neuroprotective pathways as measured in plasma. The results of this trial could provide further insight into the potential of hypoxia-based therapy as a novel treatment approach for PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: NCT05948761 (registered June 20th, 2023).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-024-03702-3","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T07:02:39Z","timestamp":1719039759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Randomized controlled trial of intermittent hypoxia in Parkinson\u2019s disease: study rationale and protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Jules M.","family":"Janssen Daalen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan J.","family":"Meinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soania","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieronymus W.H.","family":"van Hees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Ainslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick H.J.","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"3702_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JPD-219006","volume":"11","author":"K McFarthing","year":"2021","unstructured":"McFarthing K, Rafaloff G, Baptista MAS, Wyse RK, Stott SRW. Parkinson\u2019s Disease Drug therapies in the clinical Trial Pipeline: 2021 update. J Parkinsons Dis. 2021;11:891\u2013903. https:\/\/doi.org\/10.3233\/JPD-219006.","journal-title":"J Parkinsons Dis"},{"key":"3702_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/mds.28544","volume":"36","author":"J Burtscher","year":"2021","unstructured":"Burtscher J, Syed MMK, Lashuel HA, Millet GP. Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson\u2019s Disease? Mov Disord. 2021;36:857\u201361. https:\/\/doi.org\/10.1002\/mds.28544.","journal-title":"Mov Disord"},{"key":"3702_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1126\/science.aad9642","volume":"352","author":"IH Jain","year":"2016","unstructured":"Jain IH, et al. Hypoxia as a therapy for mitochondrial disease. Science. 2016;352:54\u201361. https:\/\/doi.org\/10.1126\/science.aad9642.","journal-title":"Science"},{"key":"3702_CR4","doi-asserted-by":"publisher","unstructured":"Jain IH et al. Genetic Screen for Cell Fitness in High or Low Oxygen Highlights Mitochondrial and Lipid Metabolism. Cell 181, 716\u2013727 e711, https:\/\/doi.org\/10.1016\/j.cell.2020.03.029 (2020).","DOI":"10.1016\/j.cell.2020.03.029"},{"key":"3702_CR5","doi-asserted-by":"publisher","first-page":"E4241","DOI":"10.1073\/pnas.1621511114","volume":"114","author":"M Ferrari","year":"2017","unstructured":"Ferrari M, et al. Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. Proc Natl Acad Sci U S A. 2017;114:E4241\u201350. https:\/\/doi.org\/10.1073\/pnas.1621511114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3702_CR6","doi-asserted-by":"publisher","unstructured":"Jain IH et al. Leigh Syndrome Mouse Model Can Be Rescued by Interventions that Normalize Brain Hyperoxia, but Not HIF Activation. Cell Metab 30, 824\u2013832 e823, https:\/\/doi.org\/10.1016\/j.cmet.2019.07.006 (2019).","DOI":"10.1016\/j.cmet.2019.07.006"},{"key":"3702_CR7","doi-asserted-by":"publisher","unstructured":"Ast T et al. Hypoxia Rescues Frataxin Loss by Restoring Iron Sulfur Cluster Biogenesis. Cell 177, 1507\u20131521 e1516, https:\/\/doi.org\/10.1016\/j.cell.2019.03.045 (2019).","DOI":"10.1016\/j.cell.2019.03.045"},{"key":"3702_CR8","doi-asserted-by":"publisher","first-page":"13189","DOI":"10.1096\/fj.201802655RR","volume":"33","author":"FA Khazal","year":"2019","unstructured":"Khazal FA, et al. A conditional mouse model of complex II deficiency manifesting as Leigh-Like syndrome. Faseb J. 2019;33:13189\u2013201. https:\/\/doi.org\/10.1096\/fj.201802655RR.","journal-title":"Faseb J"},{"key":"3702_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/cns.13996","volume":"29","author":"G Li","year":"2023","unstructured":"Li G, et al. Intermittent hypoxic conditioning restores neurological dysfunction of mice induced by long-term hypoxia. CNS Neurosci Ther. 2023;29:202\u201315. https:\/\/doi.org\/10.1111\/cns.13996.","journal-title":"CNS Neurosci Ther"},{"key":"3702_CR10","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.2174\/1381612811319380013","volume":"19","author":"SC Correia","year":"2013","unstructured":"Correia SC, et al. Defective HIF signaling pathway and brain response to hypoxia in neurodegenerative diseases: not an iffy question! Curr Pharm Des. 2013;19:6809\u201322. https:\/\/doi.org\/10.2174\/1381612811319380013.","journal-title":"Curr Pharm Des"},{"key":"3702_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.2009.06443.x","volume":"112","author":"SC Correia","year":"2010","unstructured":"Correia SC, Moreira PI. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration? J Neurochem. 2010;112:1\u201312. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06443.x.","journal-title":"J Neurochem"},{"key":"3702_CR12","doi-asserted-by":"publisher","first-page":"35863","DOI":"10.1074\/jbc.M005643200","volume":"275","author":"FH Agani","year":"2000","unstructured":"Agani FH, Pichiule P, Chavez JC, LaManna JC. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J Biol Chem. 2000;275:35863\u20137. https:\/\/doi.org\/10.1074\/jbc.M005643200.","journal-title":"J Biol Chem"},{"key":"3702_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF00999391","volume":"4","author":"PA Broderick","year":"1989","unstructured":"Broderick PA, Gibson GE. Dopamine and serotonin in Rat Striatum during Invivo Hypoxic-Hypoxia. Metab Brain Dis. 1989;4:143\u201353. doi:Doi 10.1007\/Bf00999391.","journal-title":"Metab Brain Dis"},{"key":"3702_CR14","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2174\/092986711797200426","volume":"18","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Yan J, Chang Y, Yan SSD, Shi H. Hypoxia Inducible Factor-1 as a target for neurodegenerative diseases. Curr Med Chem. 2011;18:4335\u201343. https:\/\/doi.org\/10.2174\/092986711797200426.","journal-title":"Curr Med Chem"},{"key":"3702_CR15","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/jnr.21988","volume":"87","author":"L Witten","year":"2009","unstructured":"Witten L, et al. HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo. J Neurosci Res. 2009;87:1686\u201394. https:\/\/doi.org\/10.1002\/jnr.21988.","journal-title":"J Neurosci Res"},{"key":"3702_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1471-4159.2003.01696.x","volume":"85","author":"PO Schnell","year":"2003","unstructured":"Schnell PO, et al. Regulation of tyrosine hydroxylase promoter activity by the Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem. 2003;85:483\u201391. https:\/\/doi.org\/10.1046\/j.1471-4159.2003.01696.x.","journal-title":"J Neurochem"},{"key":"3702_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.freeradbiomed.2013.01.026","volume":"62","author":"RE Speer","year":"2013","unstructured":"Speer RE, et al. Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by antioxidant metal chelators: from ferroptosis to stroke. Free Radic Biol Med. 2013;62:26\u201336. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.01.026.","journal-title":"Free Radic Biol Med"},{"key":"3702_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuroscience.2015.03.015","volume":"295","author":"M Smeyne","year":"2015","unstructured":"Smeyne M, Sladen P, Jiao Y, Dragatsis I, Smeyne RJ. HIF1alpha is necessary for exercise-induced neuroprotection while HIF2alpha is needed for dopaminergic neuron survival in the substantia nigra pars compacta. Neuroscience. 2015;295:23\u201338. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.03.015.","journal-title":"Neuroscience"},{"key":"3702_CR19","doi-asserted-by":"publisher","first-page":"R1181","DOI":"10.1152\/ajpregu.00208.2014","volume":"307","author":"A Navarrete-Opazo","year":"2014","unstructured":"Navarrete-Opazo A, Mitchell GS. Therapeutic potential of intermittent hypoxia: a matter of dose. Am J Physiol Regul Integr Comp Physiol. 2014;307:R1181\u20131197. https:\/\/doi.org\/10.1152\/ajpregu.00208.2014.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3702_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12877-019-1184-1","volume":"19","author":"U Bayer","year":"2019","unstructured":"Bayer U, et al. Effects of intermittent hypoxia-hyperoxia on mobility and perceived health in geriatric patients performing a multimodal training intervention: a randomized controlled trial. BMC Geriatr. 2019;19:167. https:\/\/doi.org\/10.1186\/s12877-019-1184-1.","journal-title":"BMC Geriatr"},{"key":"3702_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.resp.2008.10.012","volume":"165","author":"M Burtscher","year":"2009","unstructured":"Burtscher M, et al. Intermittent hypoxia increases exercise tolerance in patients at risk for or with mild COPD. Respir Physiol Neurobiol. 2009;165:97\u2013103. https:\/\/doi.org\/10.1016\/j.resp.2008.10.012.","journal-title":"Respir Physiol Neurobiol"},{"key":"3702_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2003.07.021","volume":"96","author":"M Burtscher","year":"2004","unstructured":"Burtscher M, et al. Intermittent hypoxia increases exercise tolerance in elderly men with and without coronary artery disease. Int J Cardiol. 2004;96:247\u201354. https:\/\/doi.org\/10.1016\/j.ijcard.2003.07.021.","journal-title":"Int J Cardiol"},{"key":"3702_CR23","doi-asserted-by":"publisher","first-page":"113890","DOI":"10.1016\/j.expneurol.2021.113890","volume":"347","author":"E Sajjadi","year":"2022","unstructured":"Sajjadi E, et al. Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: a preliminary study. Exp Neurol. 2022;347:113890. https:\/\/doi.org\/10.1016\/j.expneurol.2021.113890.","journal-title":"Exp Neurol"},{"key":"3702_CR24","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1089\/neu.2022.0120","volume":"39","author":"RD Trumbower","year":"2022","unstructured":"Trumbower RD, et al. Caffeine enhances intermittent Hypoxia-Induced gains in walking function for people with chronic spinal cord Injury. J Neurotrauma. 2022;39:1756\u201363. https:\/\/doi.org\/10.1089\/neu.2022.0120.","journal-title":"J Neurotrauma"},{"key":"3702_CR25","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1113\/JP282822","volume":"600","author":"JF Welch","year":"2022","unstructured":"Welch JF, Nair J, Argento PJ, Mitchell GS, Fox EJ. Acute intermittent hypercapnic-hypoxia elicits central neural respiratory motor plasticity in humans. J Physiol. 2022;600:2515\u201333. https:\/\/doi.org\/10.1113\/JP282822.","journal-title":"J Physiol"},{"key":"3702_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12883-022-02770-7","volume":"22","author":"JM Janssen Daalen","year":"2022","unstructured":"Janssen Daalen JM, et al. Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson\u2019s disease: study rationale and protocol. BMC Neurol. 2022;22:262. https:\/\/doi.org\/10.1186\/s12883-022-02770-7.","journal-title":"BMC Neurol"},{"key":"3702_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/ham.2018.0114","volume":"20","author":"S Dobashi","year":"2019","unstructured":"Dobashi S, Koyama K, Endo J, Kiuchi M, Horiuchi M. Impact of Dietary Nitrate supplementation on executive function during Hypoxic Exercise. High Alt Med Biol. 2019;20:187\u201391. https:\/\/doi.org\/10.1089\/ham.2018.0114.","journal-title":"High Alt Med Biol"},{"key":"3702_CR28","doi-asserted-by":"publisher","unstructured":"Horiuchi M, Ni INA, Miyazaki M, Ando D, Koyama K. Impact of Resistance Exercise under Hypoxia on Postexercise Hemodynamics in Healthy Young Males. Int J Hypertens 2018, 1456972, https:\/\/doi.org\/10.1155\/2018\/1456972 (2018).","DOI":"10.1155\/2018\/1456972"},{"key":"3702_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/thx.2010.141655","volume":"66","author":"KJ Spurling","year":"2011","unstructured":"Spurling KJ, Zammit C, Lozewicz S. Mains-powered hypoxic gas generation: a cost-effective and safe method to evaluate patients at risk from hypoxia during air travel. Thorax. 2011;66:731\u20132. https:\/\/doi.org\/10.1136\/thx.2010.141655.","journal-title":"Thorax"},{"key":"3702_CR30","doi-asserted-by":"publisher","unstructured":"Harwood B, Wright J, Burnet S. Reliability and validity of the Hypoxico Everest Summit II altitude generator. Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology 0, 1754337121995976, https:\/\/doi.org\/10.1177\/1754337121995976.","DOI":"10.1177\/1754337121995976"},{"key":"3702_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2012.02.003","volume":"18","author":"O Saeed","year":"2012","unstructured":"Saeed O, et al. Improved exercise performance and skeletal muscle strength after simulated altitude exposure: a novel approach for patients with chronic heart failure. J Card Fail. 2012;18:387\u201391. https:\/\/doi.org\/10.1016\/j.cardfail.2012.02.003.","journal-title":"J Card Fail"},{"key":"3702_CR32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0245LE","author":"I Vivodtzev","year":"2020","unstructured":"Vivodtzev I, et al. Mild to moderate sleep apnea is linked to hypoxia-induced motor recovery after spinal cord injury. Am J Respir Crit Care Med. 2020. https:\/\/doi.org\/10.1164\/rccm.202002-0245LE.","journal-title":"Am J Respir Crit Care Med"},{"key":"3702_CR33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00421-019-04096-8","volume":"119","author":"A Torpel","year":"2019","unstructured":"Torpel A, Peter B, Hamacher D, Schega L. Dose-response relationship of intermittent normobaric hypoxia to stimulate erythropoietin in the context of health promotion in young and old people. Eur J Appl Physiol. 2019;119:1065\u201374. https:\/\/doi.org\/10.1007\/s00421-019-04096-8.","journal-title":"Eur J Appl Physiol"},{"key":"3702_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1212\/01.Wnl.0000437416.34298.43","volume":"82","author":"HB Hayes","year":"2014","unstructured":"Hayes HB, et al. Daily intermittent hypoxia enhances walking after chronic spinal cord injury: a randomized trial. Neurology. 2014;82:104\u201313. https:\/\/doi.org\/10.1212\/01.Wnl.0000437416.34298.43.","journal-title":"Neurology"},{"key":"3702_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1055\/s-0030-1255067","volume":"31","author":"M Burtscher","year":"2010","unstructured":"Burtscher M, Gatterer H, Faulhaber M, Gerstgrasser W, Schenk K. Effects of intermittent hypoxia on running economy. Int J Sports Med. 2010;31:644\u201350. https:\/\/doi.org\/10.1055\/s-0030-1255067.","journal-title":"Int J Sports Med"},{"key":"3702_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3389\/fphys.2020.00531","volume":"11","author":"B Treml","year":"2020","unstructured":"Treml B, et al. Carry-over Quality of pre-acclimatization to Altitude elicited by intermittent hypoxia: a Participant-Blinded, Randomized Controlled Trial on Antedated acclimatization to Altitude. Front Physiol. 2020;11:531. https:\/\/doi.org\/10.3389\/fphys.2020.00531.","journal-title":"Front Physiol"},{"key":"3702_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1545968311412055","volume":"26","author":"RD Trumbower","year":"2012","unstructured":"Trumbower RD, Jayaraman A, Mitchell GS, Rymer WZ. Exposure to acute intermittent hypoxia augments somatic motor function in humans with incomplete spinal cord injury. Neurorehabil Neural Repair. 2012;26:163\u201372. https:\/\/doi.org\/10.1177\/1545968311412055.","journal-title":"Neurorehabil Neural Repair"},{"key":"3702_CR38","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1212\/wnl.0000000000004596","volume":"89","author":"RD Trumbower","year":"2017","unstructured":"Trumbower RD, Hayes HB, Mitchell GS, Wolf SL, Stahl VA. Effects of acute intermittent hypoxia on hand use after spinal cord trauma: a preliminary study. Neurology. 2017;89:1904\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000004596.","journal-title":"Neurology"},{"key":"3702_CR39","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin CH, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology. 2019;93:e1104\u201311. https:\/\/doi.org\/10.1212\/WNL.0000000000008088.","journal-title":"Neurology"},{"key":"3702_CR40","doi-asserted-by":"publisher","first-page":"959261","DOI":"10.3389\/fnins.2022.959261","volume":"16","author":"Y Liu","year":"2022","unstructured":"Liu Y, Dou K, Xue L, Li X, Xie A. Neurofilament light as a biomarker for motor decline in Parkinson\u2019s disease. Front Neurosci. 2022;16:959261. https:\/\/doi.org\/10.3389\/fnins.2022.959261.","journal-title":"Front Neurosci"},{"key":"3702_CR41","doi-asserted-by":"publisher","unstructured":"Joisten N, et al. Exercise diminishes plasma neurofilament light chain and reroutes the Kynurenine Pathway in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8. https:\/\/doi.org\/10.1212\/NXI.0000000000000982.","DOI":"10.1212\/NXI.0000000000000982"},{"key":"3702_CR42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41586-021-04183-x","volume":"600","author":"Z De Miguel","year":"2021","unstructured":"De Miguel Z, et al. Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature. 2021;600:494\u20139. https:\/\/doi.org\/10.1038\/s41586-021-04183-x.","journal-title":"Nature"},{"key":"3702_CR43","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang C, et al. Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2020;91:720\u20139. https:\/\/doi.org\/10.1136\/jnnp-2019-322588.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3702_CR44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3233\/JAD-150036","volume":"46","author":"W Jongbloed","year":"2015","unstructured":"Jongbloed W, et al. Clusterin levels in plasma Predict Cognitive decline and progression to Alzheimer\u2019s Disease. J Alzheimers Dis. 2015;46:1103\u201310. https:\/\/doi.org\/10.3233\/JAD-150036.","journal-title":"J Alzheimers Dis"},{"key":"3702_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-017-0319-x","volume":"9","author":"JL Hsu","year":"2017","unstructured":"Hsu JL, Lee WJ, Liao YC, Wang SJ, Fuh JL. The clinical significance of plasma clusterin and abeta in the longitudinal follow-up of patients with Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:91. https:\/\/doi.org\/10.1186\/s13195-017-0319-x.","journal-title":"Alzheimers Res Ther"},{"key":"3702_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/neu.2013.3040","volume":"31","author":"R Diaz-Arrastia","year":"2014","unstructured":"Diaz-Arrastia R, et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma. 2014;31:19\u201325. https:\/\/doi.org\/10.1089\/neu.2013.3040.","journal-title":"J Neurotrauma"},{"key":"3702_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.brainres.2018.10.006","volume":"1704","author":"F Rahmani","year":"2019","unstructured":"Rahmani F, et al. Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis. Brain Res. 2019;1704:127\u201336. https:\/\/doi.org\/10.1016\/j.brainres.2018.10.006.","journal-title":"Brain Res"},{"key":"3702_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-018-0112-1","volume":"7","author":"MA Hirsch","year":"2018","unstructured":"Hirsch MA, van Wegen EEH, Newman MA, Heyn PC. Exercise-induced increase in brain-derived neurotrophic factor in human Parkinson\u2019s disease: a systematic review and meta-analysis. Transl Neurodegener. 2018;7:7. https:\/\/doi.org\/10.1186\/s40035-018-0112-1.","journal-title":"Transl Neurodegener"},{"key":"3702_CR49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","volume":"36","author":"DJ Bowen","year":"2009","unstructured":"Bowen DJ, et al. How we design feasibility studies. Am J Prev Med. 2009;36:452\u20137. https:\/\/doi.org\/10.1016\/j.amepre.2009.02.002.","journal-title":"Am J Prev Med"},{"key":"3702_CR50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s0034-5687(97)02523-1","volume":"107","author":"JA Loeppky","year":"1997","unstructured":"Loeppky JA, et al. Ventilation during simulated altitude, normobaric hypoxia and normoxic hypobaria. Respir Physiol. 1997;107:231\u20139. https:\/\/doi.org\/10.1016\/s0034-5687(97)02523-1.","journal-title":"Respir Physiol"},{"key":"3702_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0928-4680(98)81208-X","volume":"5","author":"T Serebrovskaya","year":"1998","unstructured":"Serebrovskaya T, et al. Intermittent hypoxia (IH) improves hypoxic ventilatory sensitivity and blood dopamine (DA) in patients with Parkinson\u2019s disease (PD). Pathophysiology. 1998;5:234\u2013234. https:\/\/doi.org\/10.1016\/S0928-4680(98)81208-X.","journal-title":"Pathophysiology"},{"key":"3702_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000029507","volume":"67","author":"TV Serebrovskaya","year":"2000","unstructured":"Serebrovskaya TV, et al. Geriatric men at altitude: hypoxic ventilatory sensitivity and blood dopamine changes. Respiration. 2000;67:253\u201360. https:\/\/doi.org\/10.1159\/000029507.","journal-title":"Respiration"},{"key":"3702_CR53","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1152\/japplphysiol.00647.2017","volume":"123","author":"X Liu","year":"2017","unstructured":"Liu X, et al. Enhanced cerebral perfusion during brief exposures to cyclic intermittent hypoxemia. J Appl Physiol (1985). 2017;123:1689\u201397. https:\/\/doi.org\/10.1152\/japplphysiol.00647.2017.","journal-title":"J Appl Physiol (1985)"},{"key":"3702_CR54","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1212\/WNL.0b013e3182477ec0","volume":"78","author":"AJ Espay","year":"2012","unstructured":"Espay AJ, et al. On state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. Neurology. 2012;78:454\u20137. https:\/\/doi.org\/10.1212\/WNL.0b013e3182477ec0.","journal-title":"Neurology"},{"key":"3702_CR55","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archneur.58.9.1379","volume":"58","author":"E Cubo","year":"2001","unstructured":"Cubo E, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001;58:1379\u201382. https:\/\/doi.org\/10.1001\/archneur.58.9.1379.","journal-title":"Arch Neurol"},{"issue":"Suppl 3","key":"3702_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mds.10149","volume":"17","author":"AE Lang","year":"2002","unstructured":"Lang AE, Widner H. Deep brain stimulation for Parkinson\u2019s disease: patient selection and evaluation. Mov Disord. 2002;17(Suppl 3):94\u2013101. https:\/\/doi.org\/10.1002\/mds.10149.","journal-title":"Mov Disord"},{"key":"3702_CR57","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey Jr","year":"2001","unstructured":"Dewey RB Jr., Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385\u201392. https:\/\/doi.org\/10.1001\/archneur.58.9.1385.","journal-title":"Arch Neurol"},{"key":"3702_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-019-0099-z","volume":"5","author":"J Lucas McKay","year":"2019","unstructured":"Lucas McKay J, et al. Freezing of Gait can persist after an acute levodopa challenge in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2019;5:25. https:\/\/doi.org\/10.1038\/s41531-019-0099-z.","journal-title":"NPJ Parkinsons Dis"},{"key":"3702_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00007256-200939020-00002","volume":"39","author":"DL Bonetti","year":"2009","unstructured":"Bonetti DL, Hopkins WG. Sea-level exercise performance following adaptation to hypoxia: a meta-analysis. Sports Med. 2009;39:107\u201327. https:\/\/doi.org\/10.2165\/00007256-200939020-00002.","journal-title":"Sports Med"},{"key":"3702_CR60","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/02640410903581588","volume":"28","author":"M Faulhaber","year":"2010","unstructured":"Faulhaber M, Gatterer H, Haider T, Patterson C, Burtscher M. Intermittent hypoxia does not affect endurance performance at moderate altitude in well-trained athletes. J Sports Sci. 2010;28:513\u20139. https:\/\/doi.org\/10.1080\/02640410903581588.","journal-title":"J Sports Sci"},{"key":"3702_CR61","doi-asserted-by":"publisher","first-page":"H216","DOI":"10.1152\/ajpheart.00060.2018","volume":"315","author":"RT Mallet","year":"2018","unstructured":"Mallet RT, Manukhina EB, Ruelas SS, Caffrey JL, Downey HF. Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential. Am J Physiol Heart Circ Physiol. 2018;315:H216\u201332. https:\/\/doi.org\/10.1152\/ajpheart.00060.2018.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3702_CR62","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.trci.2017.01.002","volume":"3","author":"U Bayer","year":"2017","unstructured":"Bayer U, et al. Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients. Alzheimers Dement (N Y). 2017;3:114\u201322. https:\/\/doi.org\/10.1016\/j.trci.2017.01.002.","journal-title":"Alzheimers Dement (N Y)"},{"key":"3702_CR63","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.resp.2011.09.012","volume":"179","author":"LM Seccombe","year":"2011","unstructured":"Seccombe LM, et al. Abnormal ventilatory control in Parkinson\u2019s disease\u2013further evidence for non-motor dysfunction. Respir Physiol Neurobiol. 2011;179:300\u20134. https:\/\/doi.org\/10.1016\/j.resp.2011.09.012.","journal-title":"Respir Physiol Neurobiol"},{"key":"3702_CR64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000029224","volume":"65","author":"T Serebrovskaya","year":"1998","unstructured":"Serebrovskaya T, et al. Hypoxic ventilatory responses and gas exchange in patients with Parkinson\u2019s disease. Respiration. 1998;65:28\u201333. https:\/\/doi.org\/10.1159\/000029224.","journal-title":"Respiration"},{"key":"3702_CR65","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(05)74308-7","volume":"356","author":"G Roggla","year":"2000","unstructured":"Roggla G, Weber W, Roggla M. Parkinson\u2019s disease and impaired chemosensitivity to hypoxia. Lancet. 2000;356:2099. https:\/\/doi.org\/10.1016\/S0140-6736(05)74308-7.","journal-title":"Lancet"},{"key":"3702_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/ggi.13625","volume":"19","author":"HY Park","year":"2019","unstructured":"Park HY, Jung WS, Kim J, Lim K. Twelve weeks of exercise modality in hypoxia enhances health-related function in obese older Korean men: a randomized controlled trial. Geriatr Gerontol Int. 2019;19:311\u20136. https:\/\/doi.org\/10.1111\/ggi.13625.","journal-title":"Geriatr Gerontol Int"},{"key":"3702_CR67","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00421-020-04310-y","volume":"120","author":"B Tobin","year":"2020","unstructured":"Tobin B, Costalat G, Renshaw GMC. Intermittent not continuous hypoxia provoked haematological adaptations in healthy seniors: hypoxic pattern may hold the key. Eur J Appl Physiol. 2020;120:707\u201318. https:\/\/doi.org\/10.1007\/s00421-020-04310-y.","journal-title":"Eur J Appl Physiol"},{"key":"3702_CR68","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00421-009-1195-2","volume":"108","author":"PC de Groot","year":"2010","unstructured":"de Groot PC, Thijssen DH, Sanchez M, Ellenkamp R, Hopman MT. Ischemic preconditioning improves maximal performance in humans. Eur J Appl Physiol. 2010;108:141\u20136. https:\/\/doi.org\/10.1007\/s00421-009-1195-2.","journal-title":"Eur J Appl Physiol"},{"key":"3702_CR69","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mds.29688","volume":"39","author":"JM Janssen Daalen","year":"2024","unstructured":"Janssen Daalen JM, et al. The Hypoxia response pathway: a potential intervention target in Parkinson\u2019s Disease? Mov Disord. 2024;39:273\u201393. https:\/\/doi.org\/10.1002\/mds.29688.","journal-title":"Mov Disord"},{"key":"3702_CR70","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.2002.7938","volume":"176","author":"AM Lin","year":"2002","unstructured":"Lin AM, Chen CF, Ho LT. Neuroprotective effect of intermittent hypoxia on iron-induced oxidative injury in rat brain. Exp Neurol. 2002;176:328\u201335. https:\/\/doi.org\/10.1006\/exnr.2002.7938.","journal-title":"Exp Neurol"},{"key":"3702_CR71","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1523\/JNEUROSCI.2482-06.2007","volume":"27","author":"J Milosevic","year":"2007","unstructured":"Milosevic J, et al. Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. J Neurosci. 2007;27:412\u201321. https:\/\/doi.org\/10.1523\/JNEUROSCI.2482-06.2007.","journal-title":"J Neurosci"},{"key":"3702_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1471-4159.2010.06917.x","volume":"115","author":"JL Johansen","year":"2010","unstructured":"Johansen JL, et al. HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. J Neurochem. 2010;115:209\u201319. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06917.x.","journal-title":"J Neurochem"},{"key":"3702_CR73","doi-asserted-by":"publisher","first-page":"8043","DOI":"10.1523\/JNEUROSCI.1244-13.2014","volume":"34","author":"M Parsanejad","year":"2014","unstructured":"Parsanejad M, et al. Regulation of the VHL\/HIF-1 pathway by DJ-1. J Neurosci. 2014;34:8043\u201350. https:\/\/doi.org\/10.1523\/JNEUROSCI.1244-13.2014.","journal-title":"J Neurosci"},{"key":"3702_CR74","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2018.00121","volume":"10","author":"X Li","year":"2018","unstructured":"Li X, et al. Therapeutic potential of a Prolyl hydroxylase inhibitor FG-4592 for Parkinson\u2019s diseases in Vitro and in vivo: regulation of Redox Biology and mitochondrial function. Front Aging Neurosci. 2018;10:121. https:\/\/doi.org\/10.3389\/fnagi.2018.00121.","journal-title":"Front Aging Neurosci"},{"key":"3702_CR75","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/01902148.2020.1821263","volume":"46","author":"MA Nimje","year":"2020","unstructured":"Nimje MA, Patir H, Tirpude RK, Reddy PK, Kumar B. Physiological and oxidative stress responses to intermittent hypoxia training in Sprague Dawley rats. Exp Lung Res. 2020;46:376\u201392. https:\/\/doi.org\/10.1080\/01902148.2020.1821263.","journal-title":"Exp Lung Res"},{"key":"3702_CR76","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1177\/1535370216657614","volume":"241","author":"TV Serebrovskaya","year":"2016","unstructured":"Serebrovskaya TV, Xi L. Intermittent hypoxia training as non-pharmacologic therapy for cardiovascular diseases: practical analysis on methods and equipment. Exp Biol Med (Maywood). 2016;241:1708\u201323. https:\/\/doi.org\/10.1177\/1535370216657614.","journal-title":"Exp Biol Med (Maywood)"},{"key":"3702_CR77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1212\/WNL.0000000000200787","volume":"99","author":"JM Janssen Daalen","year":"2022","unstructured":"Janssen Daalen JM, Schootemeijer S, Richard E, Darweesh SKL, Bloem BR. Lifestyle interventions for the Prevention of Parkinson Disease: a recipe for action. Neurology. 2022;99:42\u201351. https:\/\/doi.org\/10.1212\/WNL.0000000000200787.","journal-title":"Neurology"},{"key":"3702_CR78","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/clc.22670","volume":"40","author":"O Glazachev","year":"2017","unstructured":"Glazachev O, Kopylov P, Susta D, Dudnik E, Zagaynaya E. Adaptations following an intermittent hypoxia-hyperoxia training in coronary artery disease patients: a controlled study. Clin Cardiol. 2017;40:370\u20136. https:\/\/doi.org\/10.1002\/clc.22670.","journal-title":"Clin Cardiol"},{"key":"3702_CR79","doi-asserted-by":"publisher","unstructured":"Tregub PP, et al. Molecular mechanisms of Neuroprotection after the intermittent exposures of Hypercapnic Hypoxia. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25073665.","DOI":"10.3390\/ijms25073665"},{"key":"3702_CR80","doi-asserted-by":"publisher","unstructured":"Alekseeva TM, et al. Hypercapnic hypoxia as a rehabilitation method for patients after ischemic stroke. Neurol Res. 2024;1\u201311. https:\/\/doi.org\/10.1080\/01616412.2024.2343510.","DOI":"10.1080\/01616412.2024.2343510"},{"key":"3702_CR81","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3389\/fphys.2018.01337","volume":"9","author":"A Becke","year":"2018","unstructured":"Becke A, et al. Daily Intermittent Normobaric Hypoxia over 2 weeks reduces BDNF plasma levels in young adults - a Randomized Controlled Feasibility Study. Front Physiol. 2018;9:1337. https:\/\/doi.org\/10.3389\/fphys.2018.01337.","journal-title":"Front Physiol"},{"key":"3702_CR82","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neuroscience.2016.02.060","volume":"322","author":"I Satriotomo","year":"2016","unstructured":"Satriotomo I, et al. Repetitive acute intermittent hypoxia increases growth\/neurotrophic factor expression in non-respiratory motor neurons. Neuroscience. 2016;322:479\u201388. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.02.060.","journal-title":"Neuroscience"},{"key":"3702_CR83","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jsams.2016.02.012","volume":"19","author":"L Schega","year":"2016","unstructured":"Schega L, et al. Effect of intermittent normobaric hypoxia on aerobic capacity and cognitive function in older people. J Sci Med Sport. 2016;19:941\u20135. https:\/\/doi.org\/10.1016\/j.jsams.2016.02.012.","journal-title":"J Sci Med Sport"},{"key":"3702_CR84","unstructured":"T\u00f6rpel A, Peter B, Lessmann V, Brigadski T, Schega L. in Active Healthy Ageing (2015)."},{"key":"3702_CR85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.expneurol.2009.01.017","volume":"217","author":"JE Wilkerson","year":"2009","unstructured":"Wilkerson JE, Mitchell GS. Daily intermittent hypoxia augments spinal BDNF levels, ERK phosphorylation and respiratory long-term facilitation. Exp Neurol. 2009;217:116\u201323. https:\/\/doi.org\/10.1016\/j.expneurol.2009.01.017.","journal-title":"Exp Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03702-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03702-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03702-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T07:04:59Z","timestamp":1719039899000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03702-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3702"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03702-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be performed according to the guidelines stated in the \u2018Declaration of Helsinki\u2019 from 2013 and \u2018the Medical Research Involving Human Subjects Act (WMO)\u2019 of the Civil Code of the Netherlands. This study has been reviewed and approved by the Medical Research Ethics Committee East Netherlands, The Netherlands, (reference number NL.83301.091.23) and has been registered at clinicaltrials.gov (NCT05948761, registered June 20th, 2023). Participants receive verbal and written information about the study and written informed consent will be obtained before screening. Participants are covered by trial insurance issued specifically for this study by Radboud University Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Bastiaan R. Bloem has received honoraria from serving on the scientific advisory board for Abbvie, Biogen, UCB, and Walk with Path; has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare, and Bial; and has received research support from The Netherlands Organisation for Scientific Research, the Michael J. Fox Foundation, UCB, Abbvie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, and the Parkinson Vereniging. The other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}